Sign on before you sign off.

A guide to using the Texas Prescription Monitoring Program



txpmp.org





About the Texas PMP

The Texas Prescription Monitoring Program (PMP), managed by the Texas State Board of Pharmacy, collects and monitors outpatient prescription data for all Schedule II, III, IV and V controlled substances dispensed by a pharmacy in Texas. Texas partners with more than 35 other states and organizations to share data using the PMP Interconnect.

The PMP is a patient care tool used to:

- Ensure that patients have access to safe, effective pain management.
- Visualize controlled substance data to help prescribers and pharmacists make informed prescribing and dispensing decisions.
- Avoid potentially life-threatening drug interactions.
- Address prescription drug misuse, diversion and overdose.
- Identify patients obtaining controlled substances from multiple prescribers and pharmacies, and make referrals to specialty treatment providers.

Mandated Use of the Texas PMP

The Texas PMP is part of the statewide response to the opioid epidemic. Prescribers and pharmacists or their delegates are required by Texas state law to check the PMP before prescribing or dispensing opioids, benzodiazepines, barbiturates or carisoprodol. Exceptions are made for patients who have been diagnosed with cancer or are receiving hospice care.

Checking the PMP for every patient, every time helps to eliminate implicit bias, ensuring prescribing and dispensing decisions are informed by data.



Integration

Integration provides immediate access to the Texas PMP through Electronic Health Records (EHR) and Pharmacy Management Systems (PMS). Integration greatly simplifies the process of checking the PMP, allowing providers to quickly comply with the mandate while keeping the focus on patients.

For more information about integrating the Texas PMP into your EHR or PMS, visit **txpmp.org/integration**.

Using a Delegate

The Texas PMP allows prescribers and pharmacists to authorize delegates to access patient prescription data and generate reports using the web-based PMP database. Recommended prescriber delegates include nurses, medical residents, medical assistants, administrative staff, etc. Pharmacists may delegate this responsibility to pharmacy technicians. The use of delegates saves time and can be helpful in integrating use of the Texas PMP into your workflow.



	≡ Meni											
Date of Birth:	Accent Address:		51etus of States Quered: 60212 Error for 1 or more states.	View Details V	lew Linked Record	s (7)					Offer	er Tools it
PX Summ	ary					Stat	e Indicators (2)					
Summary		0	Opioids* (excluding Supremorphine)	Buprenorphine*			atient is participation	in a specialized docks				
Total Presor	Total Prescriptions		Current Oty 137	Current Gity	48		Patient is participating in a specialized docket to address a diagnosed substance use disorder. Hx of previous overdose (3)					
Total Private Total Presori	Total Private Pay 3		ourrant MME.iday 55.00 Day Aug MME.iday 32.50	Current regiday 30 Day Avg mgiday								
Prescript	005								Details			Datumn
Prescript Total: 70	ons Private Pay: 3	Đ :	One :	arv :	Owen a		Roy :	Department :	Details Showing 1-15-th Betty 1	70 Items View	Sitema V C	1
Total: 70	Private Pay: 3	10 :	Orag 1: Overdene Antoningelse 6-325	QTY : 80.00	Days : 49	: Vie Tee	RX# : 1963398	Depenser : Cos (3475)	Showing 1-15-at		Silens V 🕐	1
Total: 70 Filled -	Private Pay: 3								Showing 1-15-st Refit :	Oaily Dose* :	Silens V 🕐	
Total: 70 Filled - 1113/2014	Private Pay: 3 Written 1 11/08/2014	4	Oxycodone-Acetaminophen 5-325	80.00	40	Vie Teo	1062358	Cos (3475)	Showing 1-15-at Refit : 0	Daily Dose* 1	Silens V 🕐	
Total: 70 Filled - 1113/2014 1101/2014	Private Pay: 3 Writes : 1108/2014 1101/2014	4	Ovycodone - Acetaminophen 5-325 Mydlocodone - Acetamin 12.325 Mg	83.00 92.00	40 90	We Teo Ti Par	1062358 91538349	Cos (3475) War(2435)	Showing 1-15-of Refit 1 0 1	Daily Dose* 1	Silens V 🕐	
Total: 70 Filed - 1113/2014 1101/2014 10/31/2014	Vinite Pay: 3 Vinites : 1108/2014 1101/2014 10/25/2014	4	Oxycodone Acetaminophen 5-325 Hydrocodone Acetamin 12.325 Mg Vyvanee 60 Mg Capeale	80.00 90.00 30.00	40 30 30	Wo Teo Ti Par Ti Par	1062358 91536249 5421541	Cos (3475) Wal (2435) Wal (2435)	Showing 1-15 at Refit 1 0 1 0	Daily Dose* 1 15:00 MME 30:00 MME	Silens V 🕐	1
Total: 70 Filled - 1113/2014 1103/2014 1003/2014 1013/2014	Private Pay: 3 Writes : 1108/2014 10025/2014 1015/2014	4 6 6	Orypodone Acetaminophes 5-325 Mydrocodone Acetamin 15.325 Mg Vyvanes 60 Mg Capeule Buperemphine 2 Mg Tablet 81	80.00 90.00 30.00 90.00	40 30 30 90	We'Tee Ti Par Ti Par Di Mar	1062308 91538349 5421541 1238449	Cos (3475) War (2435) War (2435) Ker(7123)	Showing 1-15-th Refit : 0 1 0 0	Daily Dose* : 15:00 MME 30:00 MME 2:00 mg	Silens V 🕐	
Total: 70 Filled - 1913/2014 1903/2014 19/39/2014 19/95/2014	Private Pay; 3	4 6 6 6 6	Orypodone-Acetaminophen 5-325 Mydiocodone-Acetamin 13-325 Mg Vyname 60 Mg Capesile Bupeenarphine 2 Mg Tablet 5J Hydrocodone-Acetamin 13-325 Mg	80.00 90.00 30.00 90.00	40 30 30 90 90	We'Tes Ti Par Ti Par Di Mar Ti Par	1062358 81536249 1421541 1238449 1536049	Cos (3475) Wai (2435) Ke (7123) Wai (2435)	Showing 1-15 at Refit 1 0 1 0 0 0	Daily Dose* : 15.00 MME 30.00 MME 2.00 mg 15.00 MME	Silens V 🕐	
Total: 70 Filed - 19152014 19052014 19052014 19052014 09172014	Private Pay: 3 Wittee : 1108/2014 1103/2014 10/39/20 10/30/2014 10/30/2014 10	4 6 6 6 6 6 6	Orypodone-Aestaminophen 5-325 Hydrocodone-Aostamin 13-325 Mg Vynane 60 Mg Cageale Bopreneyshne 2 Mg Tablet 81 Hydrocodone-Acetamin 13-325 Mg Orypodone-Aestaminophen 5-325	80.00 92.00 30.00 92.00 91.00 38.00	40 30 30 90 3	We Teo Ti Par Ti Par Di Mar Ti Par Ti Par	1062358 81536549 1421941 1238449 1556049 1400792	Cos (3475) War(2435) War(2435) Ke(F133) War(2435) War(2435)	Shewing 1-15-of Refit 1 0 1 0 0 0 0 0 0	Daily Dose* : 15.00 MME 30.00 MME 2.00 mg 15.00 MME	Silens V 🕐	
Total: 70 Filed - 1913/2014 1931/2014 1939/2014 1939/2014 1935/2014 091/12014 091/12014	Private Pay: 3 Whitee : 1108/2014 1103/2014 1003/2014 1013/2014 1005/2014 2015/2014 2017/2014 20	4 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	Orynodore Acetaminophen 5-325 Mydoscolaree Acetamin 13.305 Mg Vyvanee 60 Mg Capeala Beyesensyshee 23 Mg Tablet 51 Hydoscolaree Acetamin 13.305 Mg Orynodoree Acetaminophen 5-325 Phoesenino 37.5 Mg Tablet	81.00 92.00 31.00 92.00 92.00 31.00 33.00	40 30 90 90 3 3	We'Teo TrPar BrMar TrPar TrPar TrPar	1062358 51538049 1421141 1238449 1530049 1400792 1400799	Con (3475) War(2435) War(2435) Ke(F123) War(2435) War(2435) War(2435)	Sheving I-15 d Retit I 0 0 0 0 0 0 0 0 0 0	Daily Dose* : 15.00 MME 2.03 mg 15.00 MME 75.00 MME	Silens V 🕐	Dolumn 1 c
Total: 70 Filed - 1113/2014 1101/2014 1011/2014 1010/2014 1010/2014 091/12014 091/12014 091/12014	Private Pay: 3 Writes : 1106/2014 1108/2014 1008/2014 1008/2014 0017/2014 0017/2014 0017/2014	4 6 6 6 6 6 4	Orynodone Anstanirophen 5-325 Mydocodone Asstanire 13-325 Mg Vynezes 60 Mg Capsule Bispenerghine 2 Mg Tablet E1 Hydocodone Acetamic 13-325 Mg Orynodone Asstanice 13-328 Pinessurvina 375 Mg Salak Orynodone Acetamicoghen 5-325	80.00 91.00 95.00 95.00 95.00 38.00 38.00 38.00	40 30 30 80 80 3 3 30 90	We Teo Ti Par Bi-Mar Ti Par Ti Par Ti Par Ke Nos	1062358 81538049 1421541 1228449 1550049 1660752 1660752 1062358	Con (1475) mar (1435) Mar (1435) Mar (1435) Mar (1435) Mar (1435) Mar (1435) Con (1475)	Sheving 1-15 at 9 Actil 1 0 1 0 0 0 0 0 0 0 0	Carly Dose* : 1 15:00 MME 3:000 MME 2:00 mg 15:00 MME 75:00 MME	Silena V C	
Total: 70 Filed - 1113/2014 1105/2014 1005/2014 1005/2014 0917/2014 0917/2014 0917/2014 0917/2014	Private Pay: 3 Writes : 1106/2014 1101/2014 1001/2014 1001/2014 1001/2014 0011/2014 00	4 6 6 6 6 6 4 4 2	Orynodore Antaminghes 5-325 Mipliosodore Antamin 13-305 Mg Vysenes 60 Mg Capaula Biopenerghnes (Jap Bhalet El Hydrocodore Antaminghes 5-326 Meansumine 275 Mg Tablet Orynodore Antaminghes 5-325 Sis Orynodore Antaminghes 5-325	83.00 94.00 95.00 95.00 95.00 33.00 33.00 33.00 95.00	40 30 30 90 3 3 30 70 22	We Teo Ti Par Di Par Di Par Ti Par Ti Par He Not Ula Ste	1042358 91536049 1421941 1228449 1550049 1400792 1400792 1400799 1055258	Con (2475) War (2436) War (2436) Key (7436) War (2436) War (2436) Con (2436) Con (2475) War (1992)	Sheving 1-15 at 9 Attil 1 0 0 0 0 0 0 0 0 0 0 0 0 0	Carly Dose* : 1 15:00 MME 3:00 MME 2:00 mg 15:00 MME 75:00 MME 22:50 MME 20:00 MME	Silenx V C Pystripe : - - - - - - - - - - - - -	





Communication Guidelines & Talking Points

INTRODUCTION

Physicians, pharmacists and health care practitioners of allkinds often interact with patients who are experiencing pain. Sometimes prescription opioids and other medications are part of a comprehensive pain management plan. However, facilitating conversations about safe and effective alleviation of pain can be difficult, especially when you have limited time with each patient. These evidence-based health communication guidelines and talking points are designed to assist you in having effective conversations with patients about managing pain, potential opioid misuse and the Texas PMP.



THE BASICS

- Invite participation by explicitly encouraging patients to respond. Asking questions like, "How does that sound to you?" before or after providing information can help establish a trusting relationship. This can also help you collect valuable information from patients.
- Use motivational interviewing techniques such as asking open-ended questions and encouraging the patient to reflect on the positive effects of behavior change. This allows patients to explore their own circumstances, behaviors and treatment goals.
- Identify and treat psychosocial factors that contribute to patient experiences of pain. Treating co-occurring psychological disorders may help alleviate a patient's pain.
- Use positive language like, "Sometimes we struggle to know exactly what causes this problem, but I can tell you that I will make my best effort to help you get comfortable" instead of, "I don't know what's wrong." Avoid using negatives (e.g., "no""not""nothing""never"). Using positive, solution-oriented language acknowledges the patient's needs and establishes a trusting relationship.

- Affirm resilience by offering encouraging responses when patients disclose positive coping strategies. It's important to identify, name and celebrate positive coping strategies so that patients can maintain hope and realize they have the tools to cope with pain and other stressors.
- Summarize the information that patients have shared, and then keep listening. Summarizing complex reflections and leaving space for patients to interject facilitates shared understanding.
- Offer naloxone and overdose prevention counseling if you are concerned about a patient's substance use. Connect your patients to established local or state treatment and recovery services.

Still not sure if conversations about pain are going well? Focus on making sure that the patient is the one doing most of the talking. Practice listening while resisting the urge to "fix it."

Communication Basics

Talking About Pain

Guidelines	"What should I do or say?"	Guidelines	"What should I do or say?"
Provide a safe, comfortable and private space. If possible, sit alongside the patient to foster a trusting dynamic.	• "[Patient name], let's talk about how to get you comfortable. I'd like to know more about how you've managed pain in the past."	Start with open-ended questions. Ask about patients' experiences with pain and how they have managed pain in the past. Maintain eye contact and use visual cues to help you gather patient information.	 "Has there been a time in your life when you had to manage pain? What worked or didn't work before?"
Use affirmative language that fosters mutual trust. Avoid asking "Why don't you"	 "We want to make sure it's safe for you." "What about if we" 	Offer encouragement for positive or desirable pain management strategies. Ask questions to suggest alternative strategies if necessary.	 "Those are great strategies for managing pain." "Let's talk about other ways
Demonstrate empathetic, active istening by using reflective tatements and a non-judgemental	 "What I hear you saying is [paraphrase]. Is that right?" "I understand your concerns." 		to get you comfortable. Have you tried [physical therapy]?"
approach. Avoid seeming rushed and pause when necessary.	 "Does that fit with what you were thinking?" 	Consider screening patients for depression, anxiety and risk of opioid use disorder. Most pain	 "Research shows a strong connection between emotional well-being and our experience of
Before ending the conversation, use the teach-back method to ensure patient understanding. Ask patients to repeat back your mutually agreed upon	 "Can you repeat back to me what our plan is?" "Yes, and I want to remind you" 	has both physiological and psychosocial elements.	pain. Consulting with a mental health professional is one of many options that we can explore together to manage your pain."
plan using their own words. Clarify or add information when necessary.	-	If patients become upset or angry, ask about their concerns, worries, or fears. Follow up with the patient's response.	 "What are your concerns [about using acetaminophen]? Tell me more about that."
Ask patients what questions they have. Make sure they know how to get in touch if they have questions later on.	 <i>"What questions do you have?"</i> <i>"Here is how you can reach us…"</i> 	Emphasize common goals like patient comfort. Acknowledge emotions and ask open-ended questions.	 "I hear you. I understand this may be [unexpected/not what you want to discuss today]. Let's figure this out together."

Talking About Concerning PMP Data

Guidelines	"What should I do or say?"
Explain what it is, and why you are using it.	• "It is our policy to check the PMP for every patient, every time."
Summarize the PMP results to the patient and confirm the accuracy of the data.	• "I see that [summarize the Texas PMP results]. Is that correct?"
If you have concerns about PMP results, state the facts and ask non-judgemental questions to gain more information.	 "I noticed that you have been getting [drug name] from [prescriber name]. Can you tell me more about that?"
Clarify or restate clinic policies to shift the conversation to safe and effective alleviation of pain.	 "At our office, patients can only receive opioids from one prescriber. It looks like for you, that's Dr. [prescriber name]. Is that right?"
	• "Since I cannot prescribe you opioids, can we talk about other ways we can work together to alleviate your pain?"

Guidelines

If necessary, initiate a direct conversation about about dependence, misuse, opioid use disorder or overdose. If possible, facilitate a warm handoff by connecting patients to further resources.

"What should I do or say?"

- "I have some concerns, and I'd like to ask you some more questions about what you have told me."
- If necessary, refer the patient to appropriate treatment using SAMHSA resources at findtreatment.samhsa.gov.

Avoid stigmatizing language.

Use patient-centered language:

SAY THIS	NOT THAT
misuse, use other than as prescribed	abuse
person with a substance use disorder	user, addict, abuser
person in recovery, person who previously used drugs	former addict, reformed addict
negative, positive, substance-free	clean, dirty toxicology screen results

CONTACT

For help using the Texas PMP, call APPRISS at **844-4TX-4PMP (844-489-4767)**. For other general questions about the Texas PMP, contact the Texas State Board of Pharmacy at **texaspmp@pharmacy.texas.gov** or call **512-305-8050**. The Texas Health and Human Services Commission and the Texas State Board of Pharmacy have partnered to promote promote prescribers' and pharmacists' use of the Texas Prescription Monitoring Program (PMP), with the ultimate goal of preventing prescription drug misuse and overdose.

For additional information and resources, including free Continuing Education (CE) opportunities, please visit **txpmp.org.**





txpmp.org

Health and Human Services